Skip to main content
Equasens logo

Equasens — Investor Relations & Filings

Ticker · EQS ISIN · FR0012882389 LEI · 96950066I7XVFGZI8L92 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2019-02-14 Earnings Release
Country FR France
Listing PA EQS

About Equasens

https://equasens.com

Equasens is a company specializing in healthcare IT solutions for professionals and establishments. It develops and provides a range of products including professional software, electronic equipment, connected devices, and digital health solutions. The company's offerings cater to a diverse client base, including pharmacies, hospitals, nursing homes (EHPADs), home care services, and independent medical practitioners. The primary objective of its solutions is to improve the quality of patient care by facilitating the secure sharing of health data, enhancing communication between different care providers, and optimizing the coordination of care pathways across outpatient, hospital, and home care settings.

Recent filings

Filing Released Lang Actions
PHARMAGEST INTERACTIVE : chiffre d'affaires 2018
Earnings Release Classification · 1% confidence The document is dated February 14, 2019, and presents the 'Chiffre d'affaires 2018' (2018 Revenue) with detailed quarterly breakdowns and divisional performance summaries for the full fiscal year 2018. It includes financial tables, commentary on business segments, and future outlook. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often released before the full Annual Report (10-K) or the detailed management discussion (MDA). The document explicitly mentions the 'Résultats annuels 2018' release date (March 29, 2019), confirming this text is the preliminary announcement of those results. It is too detailed for a simple RPA but lacks the comprehensive scope and formal structure of a 10-K or IR. Therefore, it is classified as an Earnings Release (ER). FY 2018
2019-02-14 French
PHARMAGEST INTERACTIVE : bilan annuel 2018 du contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is a press release dated January 9, 2019, titled "BILAN ANNUEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Annual Statement of the Liquidity Contract with Gilbert Dupont Stock Brokerage Firm). It details the status of a liquidity contract as of December 31, 2018, comparing it to the previous semi-annual balance (June 30, 2018). This type of announcement, which reports on the status of a specific financial arrangement (liquidity contract) rather than comprehensive financial results (ER/IR) or management changes (MANG), fits best under general regulatory announcements or specific financial updates. Since there is no specific code for 'Liquidity Contract Update,' and it is a formal announcement regarding a financial arrangement, it is classified as a general Regulatory Filing (RNS). It is too specific for a general Earnings Release (ER) or Interim Report (IR), and it is not a transaction in own shares (POS) or capital change (CAP), but rather a report on the maintenance of market stability via a third party.
2019-01-09 French
PHARMAGEST : montée au capital de la start-up Embleema
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a strategic partnership and capital investment by Groupe Pharmagest into the startup Embleema. It details the acquisition of a 15% stake and participation in an ICO (Initial Coin Offering). This type of announcement, detailing a significant corporate transaction (investment/acquisition of shares), falls under Capital/Financing Update (CAP). Although it involves share acquisition, it is framed as a strategic investment announcement rather than a routine share repurchase (POS) or a general capital change (SHA). The presence of a future financial event date ("Publication du chiffre d'affaires 2018 : le 14 février 2019") suggests it is a standalone corporate news release, not a full periodic report (like 10-K or IR). Given the focus on subscribing to a capital increase and becoming a shareholder, CAP is the most appropriate classification.
2019-01-07 French
PHARMAGEST acquires 15% stake of French-american Start-up Embleema
Capital/Financing Update Classification · 1% confidence The document is explicitly titled '# **PRESS RELEASE**' and announces a strategic partnership and equity acquisition between Pharmagest Group and Embleema. It details the terms of the investment (acquiring a 15% stake) and the strategic rationale. This type of announcement, detailing corporate actions like investments, partnerships, and capital structure changes, falls under the 'Capital/Financing Update' category. Although it involves an equity stake acquisition, it is primarily a strategic corporate announcement rather than a formal regulatory filing like a 10-K or a simple dividend notice. It is not a transcript, an earnings release, or a report publication announcement (RPA) as it contains the full substance of the news, not just a notification that a report is available. Therefore, 'CAP' (Capital/Financing Update) is the most appropriate classification.
2019-01-07 English
PHARMAGEST INTERACTIVE: Q3 2018 revenue: + 19.20 %
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and provides key financial highlights for the third quarter (Q3 2018) and the first nine months of 2018, including revenue figures, growth percentages, and operational updates. It concludes with an outlook and a financial calendar mentioning the 'Publication of 2018 annual revenue' on a future date. This structure—a brief announcement focusing on key period results rather than the comprehensive details of a full report (like a 10-K or IR)—is characteristic of an Earnings Release (ER). It is not a full transcript (CT), a formal annual report (10-K), or a mere announcement of a report's publication (RPA), as it contains the actual results. 9M 2018
2018-11-14 English
PHARMAGEST INTERACTIVE : Chiffre d'affaires 3ème trimestre 2018 : + 19
Earnings Release Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and details financial performance metrics for the 3rd quarter (T3) and the first 9 months of 2018, including revenue figures, growth rates, and commentary on business divisions. It also mentions recent strategic partnerships and future outlook, concluding with a 'Calendrier financier' that announces the 'Publication du chiffre d'affaires 2018' for February 14, 2019. This structure—a brief announcement focusing on key financial highlights for a specific period (Q3)—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), but rather the initial release of results. 9M 2018
2018-11-14 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.